# Trump Administration Moves to Reclassify Marijuana as Schedule III Drug > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/trump-administration-cannabis-scheduling-changes/ > **Published:** 2026-04-24T19:05:59-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:11:11-04:00 > **Clinical Summary:** Explore how the Trump administration cannabis scheduling changes reduce barriers for clinical research and improve patient access to medical cannabis. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyFederal Regulation[Clinical Research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/)Medical CannabisDrug Scheduling Why This Matters Reclassification to Schedule III would reduce regulatory barriers for [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and potentially improve patient access to standardized cannabis products. This represents the most significant federal policy shift toward evidence-based [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) in decades. Clinical Summary The Trump Administration’s move to reclassify cannabis from Schedule I to Schedule III acknowledges accepted medical use while maintaining controlled substance status. Schedule III classification would allow for more robust clinical trials, standardized manufacturing processes, and potential insurance coverage. This change aligns federal policy more closely with existing state medical cannabis programs and growing clinical evidence for specific therapeutic applications. Dr. Caplan’s Take “This is the regulatory reset [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) has needed—it finally allows us to study and prescribe cannabis with the same rigor we apply to other controlled medications. The real work begins now: establishing dosing protocols, drug interactions, and quality standards that patients deserve.” Clinical Perspective 🧠 Clinicians should prepare for expanded research opportunities and potentially standardized cannabis products with consistent dosing. Patients in medical cannabis programs may see improved product quality and insurance coverage options. However, the timeline for implementation remains uncertain, and state-level programs will likely continue unchanged in the near term. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Trump%20Administration%20Moves%20to%20Reclassify%20Marijuana%20as%20Schedule%20III%20Drug%20%7C%20National%20News%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Ftrump-administration-moves-to-reclassify-marijuana-as-schedule-iii-drug-national%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Ftrump-administration-moves-to-reclassify-marijuana-as-schedule-iii-drug-national%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Trump%20Administration%20Moves%20to%20Reclassify%20Marijuana%20as%20Schedule%20III%20Drug%20%7C%20National%20News%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Ftrump-administration-moves-to-reclassify-marijuana-as-schedule-iii-drug-national%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.usnews.com/news/national-news/articles/2026-04-23/trump-administration-moves-to-reclassify-marijuana-as-schedule-iii-drug](https://www.usnews.com/news/national-news/articles/2026-04-23/trump-administration-moves-to-reclassify-marijuana-as-schedule-iii-drug) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What topics does this cannabis news article cover?](#What_topics_does_this_cannabis_news_article_cover) - [Why is this article marked as having “Notable Clinical Interest”?](#Why_is_this_article_marked_as_having_8220Notable_Clinical_Interest8221) - [What does the “New” label indicate about this article?](#What_does_the_8220New8221_label_indicate_about_this_article) - [How does federal regulation relate to clinical cannabis research?](#How_does_federal_regulation_relate_to_clinical_cannabis_research) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely. #### What topics does this cannabis news article cover? The article covers multiple areas including policy developments, federal regulation changes, clinical research updates, and medical cannabis developments. These interconnected topics reflect the evolving landscape of cannabis in healthcare and regulation. #### Why is this article marked as having “Notable Clinical Interest”? The notable clinical interest designation indicates that the content presents emerging findings or policy developments that could impact clinical practice. Healthcare providers should pay attention to these developments as they may influence patient care decisions or treatment protocols. #### What does the “New” label indicate about this article? The “New” label indicates this is recently published or updated content. This suggests the information is current and reflects the latest developments in cannabis policy, regulation, or clinical research. #### How does federal regulation relate to clinical cannabis research? Federal regulation directly impacts the availability and scope of clinical [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/). Changes in federal policy can either facilitate or restrict research opportunities, which in turn affects the evidence base for medical cannabis treatments. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump administration officially reclassifies state-licensed medical marijuana as Schedule III](https://cedclinic.com/federal-cannabis-schedule-iii-research-policy-update/) Detailed coverage of the Trump administration’s official reclassification of medical marijuana to Schedule III and its implications. [Read More](https://cedclinic.com/federal-cannabis-schedule-iii-research-policy-update/) [Schedules of Controlled Substances: Rescheduling FDA Approved Marijuana Products](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) Explore the FDA’s rescheduling of marijuana products from Schedule I to Schedule III and the related permit requirement changes. [Learn More](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) [US could reclassify marijuana today. Will it be legal in Florida?](https://cedclinic.com/federal-cannabis-reclassification-policy-changes-florida/) An analysis of potential marijuana reclassification and its legal implications in Florida and beyond. [Discover More](https://cedclinic.com/federal-cannabis-reclassification-policy-changes-florida/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).